Research
Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual agonists (tirzepatide) are highly effective for weight loss and cardiovascular risk reduction in adults with obesity.
If lifestyle changes alone haven't worked, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are injectable drugs that mimic hormones to reduce hunger and improve metabolism. They have been shown to produce significant weight loss (14-20%) and improve heart health markers.
StrongSupportsVERY_HIGH confidence
Currently available GLP-1 receptor agonists are liraglutide at a dose of 3.0 mg and semaglutide at a dose of 2.4 mg... Both liraglutide and semaglutide show beneficial effect in the treatment of patients with the risk of cardiovascular events [15,16].
Why this rating
Based on multiple large-scale trials (SCALE, STEP, SURMOUNT) cited in the review.
Source
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Karolina Kuczapska et al. · Journal of Education Health and Sport · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →